Health
Muscle Loss on GLP-1s: What the Evidence Really Shows
New body composition data compares lean mass loss on tirzepatide and semaglutide. Here is what is measured, and what remains unclear.
Jun 15, 2026
Loading
Search
Results
9 stories for“glp-1 muscle loss”
Health
Retatrutide: The Triple Agonist Still Proving Itself
Retatrutide just posted phase 3 weight loss data hitting three hormone receptors at once. Here is what is confirmed and what remains unproven.
May 27, 2026
Health
Mounjaro and Zepbound: The Case for Two Hormones at Once
Tirzepatide just beat semaglutide head to head in a major trial. Here is what SURMOUNT and SURPASS data actually shows about hitting two receptors.
Dec 9, 2024
Health
Retatrutide's Phase 3 Run Is Nearly Complete. The Numbers Are the Largest Yet
TRIUMPH-2 and TRIUMPH-3 read out in July, following TRIUMPH-1 in May. Across the programme the triple agonist has produced weight loss in a range no approved obesity drug has reached, with a filing due in early 2027.
Aug 11, 2026
Health
The Immune System Appears to Remember Obesity for Years After the Weight Has Gone
Work in EMBO Reports finds obesity leaves a chemical mark on CD4 T cells that outlasts weight loss. The authors suggest the immune system may need years of sustained maintenance to reset, and say plainly that no long term human study confirms it.
Sep 1, 2026
Health
One Receptor, Two, or Three: Comparing Semaglutide, Tirzepatide and Retatrutide
Ozempic, Mounjaro and the drug that has not arrived yet are not three versions of the same thing. They hit different receptors, produce different results, and suit different people.
Aug 11, 2026
Health
Retatrutide's Third Receptor Is the Hormone That Raises Blood Sugar. Adding It On Purpose Is the Whole Idea
Semaglutide hits one receptor and tirzepatide hits two. The third one retatrutide adds is glucagon, which does the opposite of what a diabetes drug is supposed to do. It is also where the liver results and the safety questions both come from.
Aug 20, 2026
Health
Ozempic and Wegovy: What the Trials Actually Showed
Semaglutide now has a heart disease approval too. Here is what the STEP and SELECT trial data really says, and what it does not.
Mar 13, 2024
Health
Intermittent Fasting Works About as Well as Eating Less, Because in the Trials That Is What It Turned Out to Be
Three randomised trials put time-restricted eating against ordinary calorie control or against nothing. The eating window on its own did little. Combined with eating less, it did what eating less does. What that means for anyone considering it.
Sep 6, 2026
